Literature DB >> 35554917

Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.

Corey Balinsky1, Vihasi Jani1, Peifang Sun2, Maya Williams3, Gabriel Defang2, Kevin R Porter2.   

Abstract

SARS-CoV-2 has emerged as a significant cause of morbidity and mortality worldwide. Virus neutralization assays are critical for the development and evaluation of vaccines and immunotherapeutics, as well as for conducting basic research into the immune response, spread, and pathogenesis of this disease. However, neutralization assays traditionally require the use of infectious virus which must be carefully handled in a BSL-3 setting, thus complicating the assay and restricting its use to labs with access to BSL-3 facilities. Pseudovirus-based assays are an alternative to the use of infectious virus. SARS-CoV-2 pseudovirus contains only the spike structural protein, and infection results in a single round of replication, thus allowing for the assay to be run safely under BSL-2 conditions. In this chapter, we describe protocols and considerations for the production and titration of lentivirus-based SARS-CoV-2 pseudovirus, as well as for running and analysis of FACS-based pseudovirus neutralization assays.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antibody; COVID-19; Lentivirus; Neutralization; Protocols; Pseudovirus (PV); SARS-CoV-2; Spike

Mesh:

Substances:

Year:  2022        PMID: 35554917     DOI: 10.1007/978-1-0716-2111-0_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

1.  ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.

Authors:  Hong Peng Jia; Dwight C Look; Lei Shi; Melissa Hickey; Lecia Pewe; Jason Netland; Michael Farzan; Christine Wohlford-Lenane; Stanley Perlman; Paul B McCray
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication.

Authors:  Eric C Mossel; Cheng Huang; Krishna Narayanan; Shinji Makino; Robert B Tesh; C J Peters
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 3.  Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.

Authors:  Pablo Fuentes-Prior
Journal:  J Biol Chem       Date:  2020-12-06       Impact factor: 5.157

4.  Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.

Authors:  Pranesh Padmanabhan; Rajat Desikan; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2020-12-08       Impact factor: 4.475

5.  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.

Authors:  Shibo Jiang; Christopher Hillyer; Lanying Du
Journal:  Trends Immunol       Date:  2020-04-02       Impact factor: 16.687

6.  Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.

Authors:  Xiuyuan Ou; Yan Liu; Xiaobo Lei; Pei Li; Dan Mi; Lili Ren; Li Guo; Ruixuan Guo; Ting Chen; Jiaxin Hu; Zichun Xiang; Zhixia Mu; Xing Chen; Jieyong Chen; Keping Hu; Qi Jin; Jianwei Wang; Zhaohui Qian
Journal:  Nat Commun       Date:  2020-03-27       Impact factor: 14.919

7.  The Architecture of SARS-CoV-2 Transcriptome.

Authors:  Dongwan Kim; Joo-Yeon Lee; Jeong-Sun Yang; Jun Won Kim; V Narry Kim; Hyeshik Chang
Journal:  Cell       Date:  2020-04-23       Impact factor: 41.582

8.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Authors:  Markus Hoffmann; Hannah Kleine-Weber; Simon Schroeder; Nadine Krüger; Tanja Herrler; Sandra Erichsen; Tobias S Schiergens; Georg Herrler; Nai-Huei Wu; Andreas Nitsche; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Cell       Date:  2020-03-05       Impact factor: 41.582

Review 9.  The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.

Authors:  Liangwei Duan; Qianqian Zheng; Hongxia Zhang; Yuna Niu; Yunwei Lou; Hui Wang
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

Review 10.  Characteristics of SARS-CoV-2 and COVID-19.

Authors:  Ben Hu; Hua Guo; Peng Zhou; Zheng-Li Shi
Journal:  Nat Rev Microbiol       Date:  2020-10-06       Impact factor: 78.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.